Introduction Emicizumab is an effective new treatment option for people with hemophilia A
(PwHA). The approved dosing regimens are based on body weight, without the necessity for …

Introduction Over the last decades progress in haemophilia treatment has been remarkable
and prophylaxis with clotting factor concentrates in haemophilia A and B has been …

This study presents a transversal investigation that we performed at Fundeni hospital
(Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor …

This study presents a transversal investigation, that we performed at Fundeni hospital, into
the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of …

Background: Non-replacement therapies are emerging as valuable treatments in hemophilia
patients. However, despite promising findings, there is no monitoring technique. The first …